Effect of Delayed Antiretroviral Therapy Initiation on Anti-CD4 Autoantibodies in Antiretroviral Therapy-Naive People With HIV.

J Infect DisSep 23, 2026
Clinical ResearchInfectious Diseases

Brian P Epling, Shweta Mistry, Birgit Grund et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effect of delayed antiretroviral therapy (ART) initiation on anti-CD4 autoantibodies in ART-naive individuals with HIV and CD4 > 500 cells/µL. Among 1199 participants, the prevalence of anti-CD4 autoantibodies decreased from 41% at baseline to 26% in the immediate ART group and 31% in the deferred group at month 24 (OR = 2.04; P < .001).

Key findings

  • 41% of participants had anti-CD4 autoantibodies at baseline.
  • Prevalence of anti-CD4 autoantibodies decreased to 26% in the immediate group at month 24.
  • Participants with recent HIV infection showed larger decreases in anti-CD4 autoantibodies (P < .001).
  • No difference in CD4 recovery was observed based on baseline anti-CD4 autoantibodies in the immediate group.

Why it matters

Understanding the dynamics of anti-CD4 autoantibodies in HIV-infected individuals can inform treatment strategies and patient management, particularly regarding the timing of ART initiation and its effects on immune recovery.

Source

PubMed · PMID 42047100

Published in J Infect Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.